≥75 岁老年患者血脂异常管理的专家共识

2020-06-30 中国心血管杂志.2020,25(3):201-209.

心血管疾病的发病率随增龄显著升高。在心血管疾病中,高脂血症是重要危险因素,积极控制血脂可显著降低心血管病发病率和死亡率早已为临床共识。相对于65 岁以下人群, 65 岁以上患者血脂管理的循证医学证据较

中文标题:

≥75 岁老年患者血脂异常管理的专家共识

发布机构:

发布日期:

2020-06-30

简要介绍:

心血管疾病的发病率随增龄显著升高。在心血管疾病中,高脂血症是重要危险因素,积极控制血脂可显著降低心血管病发病率和死亡率早已为临床共识。相对于65 岁以下人群, 65 岁以上患者血脂管理的循证医学证据较少,高龄(≥75 岁) 老年人群的血脂管理证据尤为不足。且老年人常合并多系统疾病、同服多种药物,因此用药还需考虑治疗成本、药物特性和相互作用、患者体能、虚弱程度以及余寿等。尤其是≥75 岁高龄老年患者,个体差异极大,而且不同的危险因素对高龄老年人的影响具有其独特性。

相关资料下载:
[AttachmentFileName(sort=1, fileName=_75岁老年患者血脂异常管理的专家共识_钱海燕.pdf)] GetToolGuiderByIdResponse(projectId=1, id=ce7a71c0019a58a5, title=≥75 岁老年患者血脂异常管理的专家共识, enTitle=, guiderFrom=中国心血管杂志.2020,25(3):201-209., authorId=0, author=, summary=心血管疾病的发病率随增龄显著升高。在心血管疾病中,高脂血症是重要危险因素,积极控制血脂可显著降低心血管病发病率和死亡率早已为临床共识。相对于65 岁以下人群, 65 岁以上患者血脂管理的循证医学证据较, cover=https://img.medsci.cn/202084/1596555085413_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Tue Jun 30 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<p style="color: #373737;">心血管疾病的发病率随增龄显著升高。在心血管疾病中,高脂血症是重要危险因素,积极控制血脂可显著降低心血管病发病率和死亡率早已为临床共识。相对于65 岁以下人群, 65 岁以上患者血脂管理的循证医学证据较少,高龄(&ge;75 岁) 老年人群的血脂管理证据尤为不足。且老年人常合并多系统疾病、同服多种药物,因此用药还需考虑治疗成本、药物特性和相互作用、患者体能、虚弱程度以及余寿等。尤其是&ge;75 岁高龄老年患者,个体差异极大,而且不同的危险因素对高龄老年人的影响具有其独特性。</p>, tagList=[TagDto(tagId=3785, tagName=血脂异常)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=19, categoryName=老年医学, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=3785, guiderKeyword=血脂异常, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8501, appHits=694, showAppHits=0, pcHits=953, showPcHits=7806, likes=7, shares=57, comments=50, approvalStatus=1, publishedTime=Tue Aug 04 23:31:58 CST 2020, publishedTimeString=2020-06-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Tue Aug 04 23:31:31 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 02:22:05 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=_75岁老年患者血脂异常管理的专家共识_钱海燕.pdf)])
_75岁老年患者血脂异常管理的专家共识_钱海燕.pdf
下载请点击:
评论区 (36)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1185733, encodeId=71751185e3336, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210920/cc1287d895a346908d9358058cdb61ff/5ef3f7950426411ea0c9966d76a74064.jpg, createdBy=1d315559103, createdName=ms6000000225486324, createdTime=Tue Jan 18 20:17:41 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971775, encodeId=a8649e1775ff, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc653915220, createdName=13889c98m27暂无昵称, createdTime=Tue Jun 08 10:49:05 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964314, encodeId=5ed49643148a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=226c4799349, createdName=654568956, createdTime=Mon May 10 17:30:14 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958541, encodeId=4f18958541df, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1303949874, createdName=78916140, createdTime=Mon Apr 19 23:29:05 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956118, encodeId=1f3d95611868, content=好文,感谢分析, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/eee8af6365ed4d459687ebdc4a62bd09/f3de335e36844f88a4515193d097be81.jpg, createdBy=9c315473229, createdName=ms1000001818983804, createdTime=Mon Apr 12 10:36:35 CST 2021, time=2021-04-12, status=1, ipAttribution=)]
    2022-01-18 ms6000000225486324

    很好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1185733, encodeId=71751185e3336, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210920/cc1287d895a346908d9358058cdb61ff/5ef3f7950426411ea0c9966d76a74064.jpg, createdBy=1d315559103, createdName=ms6000000225486324, createdTime=Tue Jan 18 20:17:41 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971775, encodeId=a8649e1775ff, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc653915220, createdName=13889c98m27暂无昵称, createdTime=Tue Jun 08 10:49:05 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964314, encodeId=5ed49643148a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=226c4799349, createdName=654568956, createdTime=Mon May 10 17:30:14 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958541, encodeId=4f18958541df, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1303949874, createdName=78916140, createdTime=Mon Apr 19 23:29:05 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956118, encodeId=1f3d95611868, content=好文,感谢分析, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/eee8af6365ed4d459687ebdc4a62bd09/f3de335e36844f88a4515193d097be81.jpg, createdBy=9c315473229, createdName=ms1000001818983804, createdTime=Mon Apr 12 10:36:35 CST 2021, time=2021-04-12, status=1, ipAttribution=)]
    2021-06-08 13889c98m27暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1185733, encodeId=71751185e3336, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210920/cc1287d895a346908d9358058cdb61ff/5ef3f7950426411ea0c9966d76a74064.jpg, createdBy=1d315559103, createdName=ms6000000225486324, createdTime=Tue Jan 18 20:17:41 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971775, encodeId=a8649e1775ff, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc653915220, createdName=13889c98m27暂无昵称, createdTime=Tue Jun 08 10:49:05 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964314, encodeId=5ed49643148a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=226c4799349, createdName=654568956, createdTime=Mon May 10 17:30:14 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958541, encodeId=4f18958541df, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1303949874, createdName=78916140, createdTime=Mon Apr 19 23:29:05 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956118, encodeId=1f3d95611868, content=好文,感谢分析, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/eee8af6365ed4d459687ebdc4a62bd09/f3de335e36844f88a4515193d097be81.jpg, createdBy=9c315473229, createdName=ms1000001818983804, createdTime=Mon Apr 12 10:36:35 CST 2021, time=2021-04-12, status=1, ipAttribution=)]
    2021-05-10 654568956

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1185733, encodeId=71751185e3336, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210920/cc1287d895a346908d9358058cdb61ff/5ef3f7950426411ea0c9966d76a74064.jpg, createdBy=1d315559103, createdName=ms6000000225486324, createdTime=Tue Jan 18 20:17:41 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971775, encodeId=a8649e1775ff, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc653915220, createdName=13889c98m27暂无昵称, createdTime=Tue Jun 08 10:49:05 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964314, encodeId=5ed49643148a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=226c4799349, createdName=654568956, createdTime=Mon May 10 17:30:14 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958541, encodeId=4f18958541df, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1303949874, createdName=78916140, createdTime=Mon Apr 19 23:29:05 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956118, encodeId=1f3d95611868, content=好文,感谢分析, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/eee8af6365ed4d459687ebdc4a62bd09/f3de335e36844f88a4515193d097be81.jpg, createdBy=9c315473229, createdName=ms1000001818983804, createdTime=Mon Apr 12 10:36:35 CST 2021, time=2021-04-12, status=1, ipAttribution=)]
    2021-04-19 78916140

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1185733, encodeId=71751185e3336, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210920/cc1287d895a346908d9358058cdb61ff/5ef3f7950426411ea0c9966d76a74064.jpg, createdBy=1d315559103, createdName=ms6000000225486324, createdTime=Tue Jan 18 20:17:41 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971775, encodeId=a8649e1775ff, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc653915220, createdName=13889c98m27暂无昵称, createdTime=Tue Jun 08 10:49:05 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964314, encodeId=5ed49643148a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=226c4799349, createdName=654568956, createdTime=Mon May 10 17:30:14 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958541, encodeId=4f18958541df, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1303949874, createdName=78916140, createdTime=Mon Apr 19 23:29:05 CST 2021, time=2021-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956118, encodeId=1f3d95611868, content=好文,感谢分析, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/eee8af6365ed4d459687ebdc4a62bd09/f3de335e36844f88a4515193d097be81.jpg, createdBy=9c315473229, createdName=ms1000001818983804, createdTime=Mon Apr 12 10:36:35 CST 2021, time=2021-04-12, status=1, ipAttribution=)]
    2021-04-12 ms1000001818983804

    好文,感谢分析

    0

拓展阅读

2010血脂异常老年人使用他汀类药物中国专家共识

中国心血管相关专家小组(统称) · 2010-01-01

2010 中国血脂异常老年人他汀类药物使用专家共识

中国老年学学会心脑血管病专业委员会 · 2010-07-01

2011ESC/EAS血脂异常指南

欧洲心脏病学会(ESC,European Society of Cardiology) · 2011-06-28

【期刊版】甘油三酯增高的血脂异常防治中国专家共识

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2011-09-10

2011年甘油三酯增高的血脂异常防治中国专家共识

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2011-09-10

2012AACE 美国内分泌医师学会血脂异常管理与动脉粥样硬化预防指南

美国临床内分泌医师学会(AACE,American Association of Clinical Endocrinologists) · 2012-03-15